Page last updated: 2024-09-04

lonafarnib and everolimus

lonafarnib has been researched along with everolimus in 3 studies

Compound Research Comparison

Studies
(lonafarnib)
Trials
(lonafarnib)
Recent Studies (post-2010)
(lonafarnib)
Studies
(everolimus)
Trials
(everolimus)
Recent Studies (post-2010) (everolimus)
22434905,6311,2894,579

Protein Interaction Comparison

ProteinTaxonomylonafarnib (IC50)everolimus (IC50)
Bile salt export pumpHomo sapiens (human)2
Serine/threonine-protein kinase mTORHomo sapiens (human)0.0022

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Laufer, S; Pillaiyar, T1
Eşkazan, AE; Özgür Yurttaş, N1
Abutaleb, NO; Atchison, L; Bedapudi, A; Cao, K; Choi, L; Gete, Y; Shores, K; Truskey, GA1

Reviews

2 review(s) available for lonafarnib and everolimus

ArticleYear
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication

2022
Novel therapeutic approaches in chronic myeloid leukemia.
    Leukemia research, 2020, Volume: 91

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Everolimus; Fusion Proteins, bcr-abl; Gene Expression; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinolones; Recombinant Proteins

2020

Other Studies

1 other study(ies) available for lonafarnib and everolimus

ArticleYear
Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome.
    Scientific reports, 2023, 03-28, Volume: 13, Issue:1

    Topics: Atherosclerosis; Calcinosis; Endothelial Cells; Everolimus; Humans; Induced Pluripotent Stem Cells; Lamin Type A; Progeria

2023